Dabiclot Capsule
Dabigatran
110mg
QbD Pharmaceuticals
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 80.00 NPR |
Available as:
Indications
Dabiclot Capsule is used for:
Prophylaxis of postoperative venous thromboembolism, Atrial fibrillation
Adult Dose
Oral
Prophylaxis of postoperative venous thromboembolism
Adult: Initially, 110 mg given w/in 1-4 hr after surgery followed by 220 mg once daily for a total of 10 days after (knee replacement) or 28-35 after (hip replacement). Reduce dose to 150 mg once daily if given concurrently w/ amiodarone, verapamil or quinidine.
Atrial fibrillation
Adult: 150 mg bid, reduce dose to 110 mg bid if given concurrently w/ verapamil.
Elderly: >75 yr 110 mg bid.
Child Dose
Renal Dose
Renal impairment:
CrCl (ml/min) Dosage Recommendation
<30 Contraindicated.
30-50 110 mg bid.
Administration
May be taken with or without food. Swallow whole, do not chew/crush.
Contra Indications
Active pathological bleeding or patient at high risk for bleeding. Patients w/ prosthetic heart valve. Severe renal impairment. Concomitant use w/ antiplatelets, other anticoagulants, thrombolytics, dronedarone, P-glycoprotein inducers (e.g. carbamazepine, rifampicin, phenytoin and St John's wort) and P-glycoprotein strong inhibitors (e.g. ciclosporin, systemic ketoconazole, itraconazole, and tacrolimus).
Precautions
Increased risk of haemorrhage and stroke. Renal and hepatic impairment. Pregnancy, lactation, elderly, childn. Monitoring Parameters Monitor renal function prior to initiation and periodically thereafter.
Pregnancy-Lactation
Interactions
May increase risk of bleeding w/ NSAIDs. Clarithromycin may increase the serum levels of dabigatran.
Potentially Fatal: P-glycoprotein inducers (e.g. carbamazepine, rifampicin, and phenytoin) decreases systemic exposure of dabigatran. P-glycoprotein strong inhibitors (e.g. ciclosporin, systemic ketoconazole, itraconazole, and tacrolimus) and dronedarone increases systemic exposure of dabigatran. Increased bleeding risk w/ antiplatelets, other anticoagulants and thrombolytics.
Adverse Effects
Side effects of Dabigatran :
GI disturbances (e.g. diarrhoea, dyspepsia and nausea); gastritis-like symptoms (e.g. oesophagitis, GI ulcer, gastric haemorrhage, haemorrhagic gastritis, GERD, erosive gastritis, haemorrhagic erosive gastritis); urticaria, pruritus, rash, allergic oedema; elevated liver enzymes.
Potentially Fatal: Anaphylaxis, anaphylactic shock, severe bleeding events.
Mechanism of Action
Dabigatran is a competitive, selective, reversible direct inhibitor of thrombin. It inhibits thrombin-induced platelet aggregation and the conversion of fibrinogen to fibrin thus preventing thrombus formation.
Note
Dabiclot 110mg Capsule manufactured by QbD Pharmaceuticals. Its generic name is Dabigatran. Dabiclot is availble in Nepal.
Farmaco Nepal drug index information on Dabiclot Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.